Abstract 2305
Background
This study aimed to examine the effects of progressive muscle relaxation (PMR) and mindfulness-based stress reduction (MBSR) on fatigue, coping styles and quality of life (QOL) in breast cancer patients receiving adjuvant paclitaxel regimen.
Methods
Participants (stages 1-3) were randomly assigned to either a 12-week (PMR) (n = 31), MBSR (n = 32) interventions or control group (CG) (n = 29). Participants in the intervention groups were instructed on PMR and MBSR, the steps of interventions were recorded a voice recorder, and were asked to listen the recorded audio files during exercises. Participants in the intervention groups continued PMR or MBSR 20 min. each day, totally 12 weeks at their home. The CG received only a single time attention placebo education (15 min.) on breast cancer before paclitaxel regimen. No intervention was applied to neither the interventions nor the control group until the follow-up assessment (week 14). Data collection tools included Patient Information Form, Brief Fatigue Inventory (BFI), Brief COPE, and the Functional Living Index-Cancer (FLIC). The data were collected at three time points including at baseline, week 12, and week 14. To analyze data repeated measures ANOVA and Kruskal Wallis tests were used.
Results
The BFI scores were significantly decreased in the MBSR, PMR groups when compared with the CG at week 12 and week 14 (p<.05). The use of emotional support, use of instrumental support, venting, positive reframing, and planning sub-dimension scores of Brief COPE were significantly higher in the MBSR, and PMR groups than the CG at week 12 and week 14 (p<.05). Besides, the humor and acceptance sub-dimension scores of Brief COPE were significantly higher in the MBSR, and PMR groups than the CG at week 14 (p<.05). Regarding FLIC, QOL scores, there were no significant differences between the groups at week 12 and week 14 (p>.05).
Conclusions
A brief, PMR and MBSR are simple and effective nursing interventions, initiated concurrently with adjuvant paclitaxel regimen that can be used to manage fatigue, and improve coping styles in patients with breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hacettepe University, Scientific Research Projects Coordination Unit (project THD-2018-17089).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract